Efferon
Austria · Biotech · Healthtech
Efferon develops blood-purification devices that remove endotoxins and excessive inflammatory mediators for critical care.
Product
Efferon develops single-use hemoadsorption devices for extracorporeal blood purification in critical care. Its technology is designed to remove bacterial endotoxins and excessive inflammatory mediators from the bloodstream.
The company offers Efferon LPS for adults and Efferon NEO for paediatric patients. Headquartered in Austria with manufacturing in Latvia, it supplies hospitals through an international distributor network.
Funding history
2 rounds · 2 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Undisclosed | €4.3M | Participants not disclosed | |
| Seed | €2.5M | Participants not disclosed |